Business Context and Reporting Period
This Form 8-K Current Report was filed by Atara Biotherapeutics, Inc. on January 4, 2018, reporting events occurring on January 3, 2018. The filing primarily announces the execution of an underwriting agreement for a public offering of common stock and includes updates to the company's risk factors and business description.
Key Financial Metrics
The filing details a capital raise rather than operational financial results. Key figures include:
- Shares Offered: 7,000,000 shares of common stock.
- Public Offering Price: $18.25 per share.
- Price to Company: $17.155 per share (net of underwriting discounts).
- Over-Allotment Option: Underwriters have a 30-day option to purchase up to 1,050,000 additional shares.
- Expected Gross Proceeds: Approximately $127,750,000 from the base offering, or $146,912,500 if the over-allotment option is fully exercised.
- Expected Closing Date: January 8, 2018.
The filing text does not provide current values for revenue, profit, cash flow, margins, or existing debt levels.
Material Changes
The primary material change is the initiation of a significant equity financing event. Additionally, the company is updating its risk factor disclosures and business description previously filed in its 2017 Form 10-Q and 2016 Form 10-K, respectively. These updates are incorporated by reference via Exhibit 99.1.
Guidance, Outlook, and Risks
The filing does not contain specific financial guidance or management commentary regarding future operational performance. However, it notes that the company is supplementing and updating risk factor disclosures and business descriptions. The offering is subject to customary closing conditions and representations, warranties, and indemnification obligations outlined in the Underwriting Agreement.
Investor Verification Checklist
- Verify the final closing of the offering on or around January 8, 2018.
- Confirm whether the underwriters exercised the option to purchase the additional 1,050,000 shares.
- Review Exhibit 99.1 for the specific updates to risk factors and business descriptions.
- Examine the Underwriting Agreement (Exhibit 1.1) for specific termination provisions and indemnification details.
- Check subsequent filings for the actual net proceeds received after deducting offering expenses.